Back to Journals » Vascular Health and Risk Management » Volume 5

Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study

Authors Baguet J, Asmar R, Valensi P, Nisse-Durgeat S, Mallion J

Published 21 January 2009 Volume 2009:5 Pages 175—183


Review by Single anonymous peer review

Peer reviewer comments 1

Download Article [PDF] 

JP Baguet1, R Asmar2, P Valensi3, S Nisse-Durgeat4, JM Mallion1

1Clinique de Cardiologie, CHU de Grenoble, Grenoble, France; 2Institut CardioVasculaire, Paris, France; 3Service d’Endocrinologie-Diabétologie-Nutrition, CHU Jean Verdier, AP-HP, Bondy, France; 4Laboratoires Takeda, Puteaux, France

Abstract: In hypertension and diabetes, early structural changes of the arterial wall precede or support atherosclerosis. There is evidence that some antihypertensive drugs exert an antiatherosclerotic effect. Over 36 months, we investigated the effect of candesartan cilexetil (CC) on the common carotid intima-media thickness (IMT) vs amlodipine besylate (AML) in patients with type 2 diabetes and mild to moderate essential hypertension. After a 4-week wash-out period, 209 patients were randomized to either CC 8 mg or AML 5 mg once daily for a minimum of 1 month, after which, if BP was not normalized, the dosage was doubled, followed by the addition of hydrochlorothiazide 12.5 mg if necessary. No significant differences were observed between the two groups for change in IMT at M12 (−0.001 vs −0.027 mm/year for CC and AML respectively, p = 0.425), at M24 (−0.033 vs −0.019 mm per year respectively, p = 0.442), and at the last visit (−0.016 vs −0.039 mm per year respectively, p = 0.549). Within the group, comparisons did not show a significant difference in changes in IMT from baseline to the three visits. At the last visit, IMT regression was observed in 52.2% of patients receiving CC and in 51.3% of those receiving AML (p = 0.908). The augmentation in carotid lumen diameter from baseline was statistically greater in the AML group at the last visit (p = 0.034). BP variations during the study were similar in the two groups. The results of this study show that CC and AML treatments may alter identically the natural progression of carotid IMT in hypertensive type 2 diabetic patients.

Keywords: hypertension, diabetes, carotid, intima-media thickness, candesartan, amlodipine

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]